Need Help? Contact Us.

Enquire now


Product Description

The PR3II test is a chemiluminescent immunoassay (CLIA), for use on IDS automated analysers. It is used for the quantitative determination of the specific IgG antibodies directed against proteinase 3 (PR3), in human samples of serum or plasma (EDTA and Heparin).

    1. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. Acta Pathol Microbiol Immunol Scand 97 ( Suppl. 6 ) : S12-S13, 1989.
    2. Jennette JC, Falk RJ. Antineutrophil cytoplasmic autoantibodies and associated diseases : a review. Am J Kidney Dis 1990; 15 : 517-29.
    3. Chen M, Kallenberg CGM. New advantages in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009, 27 (s. 52 ): 108-14. Review.
    4. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. Am J Clin Pathol 1999; 111 : 507-13.
    5. Sinico RA, Radice A, Pozzi C, et al. Diagnostic significance and antigen specificity of antineutrophil cytoplasmic antibodies in renal disease : a prospective multicentre study. Nephrol Dial Transplant 1994; 9 : 505-10.
    6. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies ( ANCA ). Autoimmunity 2005; 38 : 93-103.
    7. Vecchi M, Bianchi MB, Sinico RA, Radice A, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis : sensitivity, specificity and recognition of putative antigens. Digestion 1994; 55: 34-9.
    8. Merkel PA, Polisson RP, Chang YC, Skates SJ, et al. Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease. Ann Int Med 1997; 126: 866-73.
    9. Hagen EC, Daha MR, Andrassy K, Csernok E, et al., for the EC/BRC Project for ANCA Assay Standardization. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Unt 1998; 53: 743-53.
    10. Sinico RA, Radice A, Tonutti E, Villalta D, et al., for the Gruppo FIRMA. Proposta di linee guida per la determinazione degli anticorpi anti-citoplasma dei neutrofili ( ANCA ). Riv Med Lab-JLM 2002; 3 (4): 20-24.
    11. Savige J, Dimech W, Fritzier M, et al., for the International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120: 312-18.
    12. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predicting value of ANCA serology. Kidney Int 1998; 53: 796-8.
    13. Schmitt WH, van der Woude FJ. Clinical Applications of Antineutrophil Cytoplasmic Antibody Testing. Curr Opin Rheumatol 2004; 16(1) : 9-17.
    14. Sinico RA, Radice A, Corace C, Di Toma L, Sabadini E. Value of a New Automated Fluorescence Immunoassay (ELIA) for PR3 and MPO-ANCA in Monitoring Disease Activity in ANCA-Associated Systemic Vasculitis. Ann NY Acad Sci 2005;1050: 185-92.
    15. Mandl LA, Solomon DH, Smith EL, Lew RA, Katz JN, Shmerling RH. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Inter Med 2002; 162:1509-14.
    16. Radice A, Sinico RA. La diagnosi clinica e di laboratorio delle malattie autoimmune sistemiche: le vasculiti. In:  Il Laboratorio nelle Malattie Reumatiche Autoimmuni, R Tozzoli, N Bizzaro, D Villalta, E Tonutti, Ed. Aesculapio 2007.

Add to Enquiry Basket



Related Products

Assays Certification Platform Clinical Area Portfolio RUO/IVD
MPO CE Marked i10iSYS Vasculitis Autoimmunity IVD
GBM CE Marked iSYS Vasculitis Autoimmunity IVD
This site is registered on as a development site.